RIFAMATE Drug Patent Profile
✉ Email this page to a colleague
When do Rifamate patents expire, and what generic alternatives are available?
Rifamate is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in RIFAMATE is isoniazid; rifampin. There are five drug master file entries for this compound. Additional details are available on the isoniazid; rifampin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RIFAMATE?
- What are the global sales for RIFAMATE?
- What is Average Wholesale Price for RIFAMATE?
Summary for RIFAMATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 11 |
| Drug Prices: | Drug price information for RIFAMATE |
| DailyMed Link: | RIFAMATE at DailyMed |
US Patents and Regulatory Information for RIFAMATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | RIFAMATE | isoniazid; rifampin | CAPSULE;ORAL | 061884-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
